Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2026-01-22 @ 12:21 AM
Study NCT ID:
NCT05271318
Status:
RECRUITING
Last Update Posted:
2025-11-03
First Post:
2022-02-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Sponsor:
TILT Biotherapeutics Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TILT-T563
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |